320 related articles for article (PubMed ID: 26323213)
1. Acute vascular response to cediranib treatment in human non-small-cell lung cancer xenografts with different tumour stromal architecture.
Jiang Y; Allen D; Kersemans V; Devery AM; Bokobza SM; Smart S; Ryan AJ
Lung Cancer; 2015 Nov; 90(2):191-8. PubMed ID: 26323213
[TBL] [Abstract][Full Text] [Related]
2. The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer.
Cascone T; Xu L; Lin HY; Liu W; Tran HT; Liu Y; Howells K; Haddad V; Hanrahan E; Nilsson MB; Cortez MA; Giri U; Kadara H; Saigal B; Park YY; Peng W; Lee JS; Ryan AJ; Jüergensmeier JM; Herbst RS; Wang J; Langley RR; Wistuba II; Lee JJ; Heymach JV
Clin Cancer Res; 2017 Sep; 23(18):5489-5501. PubMed ID: 28559461
[No Abstract] [Full Text] [Related]
3. Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts.
Smith NR; James NH; Oakley I; Wainwright A; Copley C; Kendrew J; Womersley LM; Jürgensmeier JM; Wedge SR; Barry ST
Mol Cancer Ther; 2007 Aug; 6(8):2198-208. PubMed ID: 17699717
[TBL] [Abstract][Full Text] [Related]
4. Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis.
Takahashi O; Komaki R; Smith PD; Jürgensmeier JM; Ryan A; Bekele BN; Wistuba II; Jacoby JJ; Korshunova MV; Biernacka A; Erez B; Hosho K; Herbst RS; O'Reilly MS
Clin Cancer Res; 2012 Mar; 18(6):1641-54. PubMed ID: 22275507
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of vascular endothelial growth factor signalling using cediranib (RECENTIN; AZD2171) enhances radiation response and causes substantial physiological changes in lung tumour xenografts.
Williams KJ; Telfer BA; Shannon AM; Babur M; Stratford IJ; Wedge SR
Br J Radiol; 2008 Oct; 81 Spec No 1():S21-7. PubMed ID: 18819995
[TBL] [Abstract][Full Text] [Related]
6. Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy.
Friess T; Scheuer W; Hasmann M
Clin Cancer Res; 2005 Jul; 11(14):5300-9. PubMed ID: 16033849
[TBL] [Abstract][Full Text] [Related]
7. RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways.
Feng Y; Hu J; Ma J; Feng K; Zhang X; Yang S; Wang W; Zhang J; Zhang Y
Eur J Cancer; 2011 Oct; 47(15):2353-63. PubMed ID: 21680174
[TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer.
Cao C; Albert JM; Geng L; Ivy PS; Sandler A; Johnson DH; Lu B
Cancer Res; 2006 Dec; 66(23):11409-15. PubMed ID: 17145887
[TBL] [Abstract][Full Text] [Related]
9. Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family.
Brave SR; Ratcliffe K; Wilson Z; James NH; Ashton S; Wainwright A; Kendrew J; Dudley P; Broadbent N; Sproat G; Taylor S; Barnes C; Silva JC; Farnsworth CL; Hennequin L; Ogilvie DJ; Jürgensmeier JM; Shibuya M; Wedge SR; Barry ST
Mol Cancer Ther; 2011 May; 10(5):861-73. PubMed ID: 21441409
[TBL] [Abstract][Full Text] [Related]
10. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.
Xie M; He CS; Wei SH; Zhang L
Eur J Cancer; 2013 Nov; 49(16):3559-72. PubMed ID: 23916913
[TBL] [Abstract][Full Text] [Related]
11. PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo.
Rudin M; McSheehy PM; Allegrini PR; Rausch M; Baumann D; Becquet M; Brecht K; Brueggen J; Ferretti S; Schaeffer F; Schnell C; Wood J
NMR Biomed; 2005 Aug; 18(5):308-21. PubMed ID: 15918178
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor directly stimulates tumour cell proliferation in non-small cell lung cancer.
Devery AM; Wadekar R; Bokobza SM; Weber AM; Jiang Y; Ryan AJ
Int J Oncol; 2015 Sep; 47(3):849-56. PubMed ID: 26179332
[TBL] [Abstract][Full Text] [Related]
13. Antitumor and antiangiogenic activity of cediranib in a preclinical model of renal cell carcinoma.
Medinger M; Esser N; Zirrgiebel U; Ryan A; Jürgensmeier JM; Drevs J
Anticancer Res; 2009 Dec; 29(12):5065-76. PubMed ID: 20044618
[TBL] [Abstract][Full Text] [Related]
14. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
[TBL] [Abstract][Full Text] [Related]
15. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
Amino N; Ideyama Y; Yamano M; Kuromitsu S; Tajinda K; Samizu K; Hisamichi H; Matsuhisa A; Shirasuna K; Kudoh M; Shibasaki M
Clin Cancer Res; 2006 Mar; 12(5):1630-8. PubMed ID: 16533791
[TBL] [Abstract][Full Text] [Related]
16. The VEGFR Inhibitor Cediranib Improves the Efficacy of Fractionated Radiotherapy in a Colorectal Cancer Xenograft Model.
Melsens E; Verberckmoes B; Rosseel N; Vanhove C; Descamps B; Pattyn P; Ceelen W
Eur Surg Res; 2017; 58(3-4):95-108. PubMed ID: 28002822
[TBL] [Abstract][Full Text] [Related]
17. Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation.
Vlahovic G; Rabbani ZN; Herndon JE; Dewhirst MW; Vujaskovic Z
Br J Cancer; 2006 Oct; 95(8):1013-9. PubMed ID: 17003785
[TBL] [Abstract][Full Text] [Related]
18. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
19. Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors.
Morgillo F; Cascone T; D'Aiuto E; Martinelli E; Troiani T; Saintigny P; De Palma R; Heymach JV; Berrino L; Tuccillo C; Ciardiello F
Br J Cancer; 2011 Jul; 105(3):382-92. PubMed ID: 21750552
[TBL] [Abstract][Full Text] [Related]
20. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.
Wedge SR; Kendrew J; Hennequin LF; Valentine PJ; Barry ST; Brave SR; Smith NR; James NH; Dukes M; Curwen JO; Chester R; Jackson JA; Boffey SJ; Kilburn LL; Barnett S; Richmond GH; Wadsworth PF; Walker M; Bigley AL; Taylor ST; Cooper L; Beck S; Jürgensmeier JM; Ogilvie DJ
Cancer Res; 2005 May; 65(10):4389-400. PubMed ID: 15899831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
